A case of relapsed/refractory peripheral T-cell lymphoma treated with EZH2 inhibitors and literature review

doi:10.3760/cma.j.cn441417-20250110-13029

Abstract

Abstract:

This article reports a case of relapsed/refractory peripheral T-cell lymphoma treated with an enhancer of zeste homolog 2 (EZH2) inhibitor. Peripheral T-cell lymphoma is a rare and highly heterogeneous and aggressive lymphoproliferative disease originating from post-thymic mature T cells or mature NK cells, characterized by a poor overall prognosis and a high recurrence rate after first-line treatment. There are limited treatment options for relapsed/refractory peripheral T-cell lymphoma. EZH2 is a histone methyltransferase widely expressed in various tumor cells, and its expression is associated with the progression and poor prognosis of peripheral T-cell lymphoma. Therefore, inhibiting EZH2 activity has become a therapeutic target for relapsed/refractory peripheral T-cell lymphoma.

Key words: Peripheral T-cell lymphoma, , Recurrence, , Zeste enhancer homolog 2 inhibitors

摘要：

本文报道了1例Zeste增强子同源物2（enhancer of zeste homolog 2，EZH2）抑制剂治疗复发/难治性外周T细胞淋巴瘤患者。外周T细胞淋巴瘤是一组起源于胸腺后成熟T细胞或成熟NK细胞罕见的、具有高度异质性和侵袭性的淋巴组织增生性疾病，整体预后差，一线治疗后复发率高。复发/难治性外周T细胞淋巴瘤治疗选择很少。EZH2是一种组蛋白甲基转移酶，广泛存在于多种肿瘤细胞中，EZH2表达与外周T细胞淋巴瘤进展、预后不良有关。因此，抑制EZH2活性已成为复发/难治性外周T细胞淋巴瘤的治疗靶点。

关键词: 外周T细胞淋巴瘤, 复发, Zeste增强子同源物2抑制剂

Zhang Ziwei, Yan Jiaxin, Gao Na.

A case of relapsed/refractory peripheral T-cell lymphoma treated with EZH2 inhibitors and literature review [J]. International Medicine and Health Guidance News, 2025, 31(13): 2256-2259.

仉紫薇颜嘉欣高娜.

EZH2抑制剂治疗复发/难治性外周T细胞淋巴瘤1例并文献复习 [J]. 国际医药卫生导报, 2025, 31(13): 2256-2259.

References

[1]Alaggio R, Amador C, Anagnostopoulos I, A et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms[J]. Leukemia, 2022, 36(7): 1720-1748. DOI: 10.1038/s41375-022-01620-2.

[2]Vose J, Armitage J, Weisenburger D, et al. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes[J]. J Clin Oncol, 2008, 26(25): 4124-4130. DOI: 10.1200/JCO.2008.16.4558.

[3]Zing NPC, Fischer T, Zain J, et al. Peripheral T-cell lymphomas: incorporating new developments in diagnostics, prognostication, and treatment into clinical practice-part 1: PTCL-NOS, FTCL, AITL, ALCL[J]. Oncology (Williston Park), 2018, 32(7): e74-e82.

[4]Fiore D, Cappelli LV, Broccoli A, et al. Peripheral T cell lymphomas: from the bench to the clinic[J]. Nat Rev Cancer, 2020, 20(6): 323-342. DOI: 10.1038/s41568-020-0247-0.

[5]Luan Y, Li X, Luan Y, et al. Therapeutic challenges in peripheral T-cell lymphoma[J]. Mol Cancer, 2024, 23(1): 2. DOI: 10.1186/s12943-023-01904-w.

[6]Bellei M, Chiattone CS, Luminari S, et al. T-cell lymphomas in South America and Europe[J]. Rev Bras Hematol Hemoter, 2012, 34(1): 42-47. DOI:10.5581/1516-8484.20120013.

[7]Oluwasanjo A, Kartan S, Johnson W, et al. Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) [J]. Cancer Treat Res, 2019, 176: 83-98. DOI: 10.1007/978-3-319-99716-2_4.

[8]Lansigan F, Horwitz SM, Pinter-Brown LC, et al. Outcomes for relapsed and refractory peripheral T-cell lymphoma patients after front-line therapy from the COMPLETE registry[J]. Acta Haematol, 2020, 143(1): 40-50. DOI: 10.1159/000500666.

[9]Liu Y, Yang Q. The roles of EZH2 in cancer and its inhibitors[J]. Med Oncol, 2023,40(6): 167. DOI:10.1007/s12032-023-02025-6.

[10]Pasini D, Di Croce L. Emerging roles for polycomb proteins in cancer[J]. Curr Opin Genet Dev, 2016, 36: 50-58. DOI:10.1016/j.gde.2016.03.013.

[11]Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics[J]. Mutat Res, 2008, 647(1-2): 21-29. DOI: 10.1016/j.mrfmmm.2008.07.010.

[12]Xu K, Wu ZJ, Groner AC, et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is polycomb-independent[J]. Science, 2012, 338(6113): 1465-1469. DOI: 10.1126/science.1227604.

[13]Kim E, Kim M, Woo DH, et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells[J]. Cancer Cell, 2013, 23(6): 839-852. DOI: 10.1016/j.ccr.2013.04.008.

[14]Kim J, Lee Y, Lu X, et al. Polycomb- and methylation-independent roles of EZH2 as a transcription activator[J]. Cell Rep, 2018, 25(10): 2808-2820.e4. DOI: 10.1016/j.celrep.2018.11.035.

[15]Zimmerman SM, Lin PN, Souroullas GP. Non-canonical functions of EZH2 in cancer[J]. Front Oncol, 2023, 13: 1233953. DOI: 10.3389/fonc.2023.1233953.

[16]Kim KH, Roberts CW. Targeting EZH2 in cancer[J]. Nat Med, 2016, 22(2): 128-134. DOI: 10.1038/nm.4036.

[17]Shi M, Shahsafaei A, Liu C, et al. Enhancer of zeste homolog 2 is widely expressed in T-cell neoplasms, is associated with high proliferation rate and correlates with MYC and pSTAT3 expression in a subset of cases[J]. Leuk Lymphoma, 2015, 56(7): 2087-2091. DOI: 10.3109/10428194.2014.968780.

[18]Jiang T, Wang Y, Zhou F, et al. Prognostic value of high EZH2 expression in patients with different types of cancer: a systematic review with meta-analysis[J]. Oncotarget, 2016 , 7(4):4584-4597. DOI: 10.18632/oncotarget.6612.

[19]Tian X, Pelton A, Shahsafaei A, et al. Differential expression of enhancer of zeste homolog 2 (EZH2) protein in small cell and aggressive B-cell non-Hodgkin lymphomas and differential regulation of EZH2 expression by p-ERK1/2 and MYC in aggressive B-cell lymphomas[J]. Mod Pathol, 2016,29(9): 1050-1057. DOI:10.1038/modpathol.2016.114.

[20]Herviou L, Cavalli G, Cartron G, et al. EZH2 in normal hematopoiesis and hematological malignancies[J]. Oncotarget, 2016, 7(3): 2284-2296. DOI: 10.18632/oncotarget.6198.

[21]Tian X, Xu J, Fletcher C, et al. Expression of enhancer of zeste homolog 2 (EZH2) protein in histiocytic and dendritic cell neoplasms with evidence for p-ERK1/2-related, but not MYC- or p-STAT3-related cell signaling[J]. Mod Pathol, 2018, 31(4):553-561. DOI: 10.1038/modpathol.2017.174.

[22]Tian X, Xu J, Dorfman DM. Utility of combined EZH2, p-ERK1/2, p-STAT, and MYC expression in the differential diagnosis of EZH2-positive hodgkin lymphomas and related large B-cell lymphomas[J]. Am J Surg Pathol, 2019, 43(1):102-109. DOI: 10.1097/PAS.0000000000001180.

[23]Martinez-Baquero D, Sakhdari A, Mo H, et al. EZH2 expression is associated with inferior overall survival in mantle cell lymphoma[J]. Mod Pathol, 2021, 34(12): 2183-2191. DOI: 10.1038/s41379-021-00885-9.

[24]Fujikawa D, Nakagawa S, Hori M, et al. Polycomb-dependent epigenetic landscape in adult T-cell leukemia[J]. Blood, 2016, 127(14): 1790-1802. DOI: 10.1182/blood-2015-08-662593.

[25]Song Y, Jin Z, Li ZM, et al. Enhancer of zeste homolog 2 inhibitor SHR2554 in relapsed or refractory peripheral T-cell lymphoma: data from the first-in-human phase I study[J]. Clin Cancer Res, 2024, 30(7): 1248-1255. DOI: 10.1158/1078-0432.CCR-23-2582.